Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides

被引:24
|
作者
Roth, CM [1 ]
机构
[1] Rutgers State Univ, Dept Chem & Biochem Engn, Dept Biomed Engn, Piscataway, NJ 08854 USA
关键词
D O I
10.1529/biophysj.104.054080
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Antisense oligonucleotides present a powerful means to inhibit expression of specific genes, but their effectiveness is limited by factors including cellular delivery, biochemical attack, and poor binding to target. We have developed a systems model of the processes required for an antisense oligonucleotide to enter, gain access to its target mRNA, and exert activity in a cell. The model accurately mimics observed trends in antisense effectiveness with the stability of the oligonucleotide backbone and with the affinity/kinetics of binding to the mRNA over the time course of inhibition. By varying the model parameters within the physically realizable range, we note that the major molecular and cellular barriers to antisense effectiveness are intracellular trafficking, oligonucleotide-mRNA binding rate, and nuclease degradation of oligonucleotides, with a weaker dependence on total cellular uptake than might be expected. Furthermore, the model may serve as a predictive tool to design and test strategies for the cellular use of antisense oligonucleotides. The use of integrated mathematical modeling can play a significant role in the development of antisense and related technologies.
引用
收藏
页码:2286 / 2295
页数:10
相关论文
共 50 条
  • [31] Pharmacology of antisense oligonucleotides
    Dean, NM
    Cooper, SR
    Shanahan, W
    Taylor, J
    Myers, K
    JOURNAL OF CLINICAL LIGAND ASSAY, 2000, 23 (01): : 43 - 49
  • [32] PHARMACOKINETICS OF ANTISENSE OLIGONUCLEOTIDES
    AGRAWAL, S
    TEMSAMANI, J
    GALBRAITH, W
    TANG, JY
    CLINICAL PHARMACOKINETICS, 1995, 28 (01) : 7 - 16
  • [33] Antisense oligonucleotides in cancer
    Castanotto, Daniela
    Stein, Cy A.
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (06) : 584 - 589
  • [34] CHARACTERIZATION OF ANTISENSE OLIGONUCLEOTIDES
    AGRAWAL, S
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1994, 208 : 153 - ANYL
  • [35] Conjugated antisense oligonucleotides
    Manoharan, M
    Tivel, KL
    Condon, TP
    Andrade, LK
    BarberPeoch, I
    Inamati, G
    Shah, S
    Mohan, V
    Graham, MJ
    Bennett, CF
    Crooke, ST
    Cook, PD
    NUCLEOSIDES & NUCLEOTIDES, 1997, 16 (7-9): : 1129 - 1138
  • [36] Antisense oligonucleotides for neurodegeneration
    Leavitt, Blair R.
    Tabrizi, Sarah J.
    SCIENCE, 2020, 367 (6485) : 1428 - 1429
  • [37] Specificity of antisense oligonucleotides
    Tidd, DM
    PERSPECTIVES IN DRUG DISCOVERY AND DESIGN, 1996, 4 : 51 - 60
  • [38] Antisense oligonucleotides for diabetes
    不详
    DIABETES OBESITY & METABOLISM, 2000, 2 (06): : 390 - 391
  • [39] Antisense oligonucleotides in neuroendocrinology
    Neumann, ID
    METHODS-A COMPANION TO METHODS IN ENZYMOLOGY, 2000, 22 (03): : 195 - 196
  • [40] Antisense oligonucleotides in cancerology
    Bertrand, JR
    Helin, V
    Fattal, E
    Couvreur, P
    Malvy, C
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 988 - 988